Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Multisite, Double-blinded Randomized Trial of BNT327 in Combination With Chemotherapy (Etoposide/Carboplatin) Compared to Atezolizumab in Combination With Chemotherapy (Etoposide/Carboplatin) in Participants With First-line Extensive-stage Small-cell Lung Cancer

NCT06712355 is registered in ClinicalTrials.gov with BioNTech SE as lead sponsor.

NCT NCT06712355
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06712355 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Multisite, Double-blinded Randomized Trial of BNT327 in Combination With Chemotherapy (Etoposide/Carboplatin) Compared to Atezolizumab in Combination With Chemotherapy (Etoposide/Carboplatin) in Participants With First-line Extensive-stage Small-cell Lung Cancer
Lead sponsor
BioNTech SE
Phase
Phase 3
Overall status
Recruiting
Start date
February 3, 2025
Completion date
July 31, 2029
Enrollment
621 (estimated)
Sites
225

Conditions

As the registry lists them; a condition with its own page is linked.

extensive-stage small-cell lung cancer